DCM
CARM

Driehaus Capital Management’s Carisma Therapeutics CARM Stock Holding History

Driehaus Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-166,612
Closed -$4.73M – 409
2018
Q4 		$4.73M Sell
166,612
-14,586
-8% -$465K 0.2% 135
2018
Q3 		$7.79M Sell
181,198
-4,665
-3% -$182K 0.24% 132
2018
Q2 		$7.25M Buy
+185,863
New +$8.19M 0.25% 127

Other funds holding CARM

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Driehaus Capital Management's CARM Position: Q1 2019 in Review

Driehaus Capital Management sold out of Carisma Therapeutics (CARM) in Q1 2019, closing a stake of 166,612 shares — an estimated $4.73M sold.

Driehaus Capital Management first reported a position in CARM in Q2 2018 and held it in 3 quarters. The position peaked at $7.79M in Q3 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q1 2019.

  • Driehaus Capital Management reported no remaining Carisma Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Driehaus Capital Management sold 166,612 Carisma Therapeutics shares in Q1 2019, an estimated $4.73M.
  • Driehaus Capital Management first reported a position in Carisma Therapeutics in Q2 2018 and held it in 3 quarters.
  • Driehaus Capital Management's Carisma Therapeutics position peaked at $7.79M in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2019.

Based on Driehaus Capital Management's 13F filing for Q1 2019, filed 15 May 2019.